Falang Database driver not enabled

Eyevensys closes a $30M Series B Financing

Eyevensys is a clinical-stage biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases. The company has completed a $30M Series B financing round. The tour was led by Boehringer Ingelheim Venture Fund and included participation from CapDecisif Management, Pontifax, Bpifrance, Inserm Transfert, and Global Health Sciences.